CARDIAC DRUG-DRUG INTERACTION STUDIES CONDUCTED ON HEALTHY PEOPLE: A SYSTEMATIC REVIEW
Main Article Content
Patients with cardiovascular disease have a higher prevalence of drug interactions than other patient groups. Drug interactions may result from pharmacokinetic or pharmacodynamic mechanisms. This study is a systematic review that aims to identify drug interactions related to cardiac drugs. Article searches were conducted on PubMed and ScienceDirect databases to identify all articles on cardiac drug-drug interaction studies. The search started from articles published in 2013 to 2023. The keywords used in the article search were as follows: drug-drug interactions, cardiac patient, cardiac drug, cardiovascular drug, pharmacokinetics interaction, pharmacodynamic interaction combined with the boolean operator "AND". Study articles that met the requirements were entered into the study for review. The total number of articles identified from the database used was 805 articles; 7 duplicate articles were excluded; 84 articles were available in full text; but only 30 articles in accordance with the inclusion were reviewed. Potential drug interactions related to cardiac drugs were most common in the Angiotensin II Receptor Blocker (ARB) class of drugs. Other cardiac drug interactions occurred with angiotensin receptor-neprilysin inhibitors (ARNI), anticoagulants, antiplatelets, digoxin, calcium channel blockers and beta blockers. The effects of these cardiac drug interactions vary. To avoid the occurrence of drug interactions, co-administration of cardiac drugs should be administered with caution, dose adjustments may be required, and monitoring for possible adverse drug events should be done.
Al-Jabi, S.W., Aldabe, L., Alhaj-Asaad, L., Thaher, M., Zyoud, S.H., and Sweileh, W.M., 2021. Assessment of drug interactions and their associated factors among patients with cardiovascular diseases: a cross-sectional study from the occupied Palestinian territory. Lancet (London, England), 398, S8.
Assefa, Y.A., Kedir, A., and Kahaliw, W., 2020. Survey on Polypharmacy and Drug-Drug Interactions Among Elderly People with Cardiovascular Diseases at Yekatit 12 Hospital, Addis Ababa, Ethiopia. Integrated Pharmacy Research and Practice, Volume 9, 1–9.
Ayalasomayajula, S., Schuehly, U., Pal, P., Chen, F., Zhou, W., Sunkara, G., and Langenickel, T.H., 2018. Effect of the angiotensin receptor–neprilysin inhibitor sacubitril/valsartan on the pharmacokinetics and pharmacodynamics of a single dose of furosemide. British Journal of Clinical Pharmacology, 84 (5), 926–936.
Delavenne, X., Magnin, M., Basset, T., Piot, M., Mallouk, N., Ressnikoff, D., Garcin, A., Laporte, S., Garnier, P., and Mismetti, P., 2013. Investigation of drug-drug interactions between clopidogrel and fluoxetine. Fundamental and Clinical Pharmacology, 27 (6), 683–689.
Frost, C.E., Byon, W., Song, Y., Wang, J., Schuster, A.E., Boyd, R.A., Zhang, D., Yu, Z., Dias, C., Shenker, A., and Lacreta, F., 2015. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. British Journal of Clinical Pharmacology, 79 (5), 838–846.
Gan, L., Jiang, X., Mendonza, A., Swan, T., Reynolds, C., Nguyen, J., Pal, P., Neelakantham, S., Dahlke, M., Langenickel, T., Rajman, I., Akahori, M., Zhou, W., Rebello, S., and Sunkara, G., 2016. Pharmacokinetic drug-drug interaction assessment of LCZ696 (an angiotensin receptor neprilysin inhibitor) with omeprazole, metformin or levonorgestrel-ethinyl estradiol in healthy subjects. Clinical Pharmacology in Drug Development, 5 (1), 27–39.
Gundlach, K., Wolf, K., Salem, I., Randerath, O., and Seiler, D., 2021. Safety of Candesartan, Amlodipine,
and Atorvastatin in Combination: Interaction Study in Healthy Subjects. Clinical Pharmacology in Drug Development, 10 (2), 190–197.
Hobl, E.L., Reiter, B., Schoergenhofer, C., Schwameis, M., Derhaschnig, U., Kubica, J., Stimpfl, T., and Jilma, B., 2016. Morphine decreases ticagrelor concentrations but not its antiplatelet effects: A randomized trial in healthy volunteers. European Journal of Clinical Investigation, 46 (1), 7–14.
Hobl, E.L., Stimpfl, T., Ebner, J., Schoergenhofer, C., Derhaschnig, U., Sunder-Plassmann, R., Jilma-Stohlawetz, P., Mannhalter, C., Posch, M., and Jilma, B., 2014. Morphine decreases clopidogrel concentrations and effects: A randomized, double-blind, placebo-controlled trial. Journal of the American College of Cardiology, 63 (7), 630–635.
Hunt, T.L., Tzanis, E., Bai, S., Manley, A., Chitra, S., and McGovern, P.C., 2021. The Effect of Verapamil, a P-gp Inhibitor, on the Pharmacokinetics, Safety, and Tolerability of Omadacycline in Healthy Adults: A Phase I, Open-Label, Single-Sequence Study. European Journal of Drug Metabolism and Pharmacokinetics, 46 (1), 85–92.
Jeddi, F.R., Nabovati, E., Peykani, F., Anvari, S., and Toolaroud, P.B., 2022. Potential Drug-Drug Interactions in a Cardiac Center: Development of Simple Software for Pattern Identification. Journal of Tehran University Heart Center, 17 (4), 215–222.
Kirigaya, Y., Shiramoto, M., Ishizuka, T., Uchimaru, H., Irie, S., Kato, M., Shimizu, T., Nakatsu, T., Nishikawa, Y., and Ishizuka, H., 2020. Pharmacokinetic interactions of esaxerenone with amlodipine and digoxin in healthy Japanese subjects. BMC Pharmacology and Toxicology, 21 (1), 1–10.
Lee, J., Lee, H., Jang, K., Lim, K.S., Shin, D., and Yu, K.S., 2014. Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers. Drug Design, Development and Therapy, 8, 1781–1788.
Manitpisitkul, P., Curtin, C.R., Shalayda, K., Wang, S.S., Ford, L., and Heald, D., 2014. Pharmacokinetic interactions between topiramate and diltiazem, hydrochlorothiazide, or propranolol. Clinical Pharmacology in Drug Development, 3 (5), 378–387.
Moon, S.J., Jeon, J.Y., Jang, K., Yu, K.S., Lim, Y., and Kim, M.G., 2019. Pharmacokinetic interactions between telmisartan/ amlodipine and rosuvastatin after multiple oral administrations in healthy Korean male subjects. Drug Design, Development and Therapy, 13, 2533–2542.
Moon, S.J., Jeon, J.Y., Yu, K.S., and Kim, M.G., 2019. Pharmacokinetic Interaction Among Telmisartan, Amlodipine, and Hydrochlorothiazide After a Single Oral Administration in Healthy Male Subjects. Clinical Therapeutics, 41 (11), 2273–2282.
Prastiya, U. and Maulani, D., 2022. Potensi Interaksi Obat Bisoprolol Pada Pasien BPJS Rawat Jalan di Poli Jantung Rumah Sakit Al-Huda Banyuwangi (Periode Januari-Maret 2022), 5 (No.2), 64–71.
Roh, H., Son, H., Lee, D., Chang, H., Yun, C., and Park, K., 2014. Pharmacokinetic interaction between rosuvastatin and olmesartan: A randomized, open-label, 3-period, multiple-dose crossover study in healthy Korean male subjects. Clinical Therapeutics, 36 (8), 1159–1170.
Seong, S.J., Ohk, B., Kang, W.Y., Gwon, M.R., Kim, B.K., Cho, S., Yang, D.H., Lee, H.W., and Yoon, Y.R., 2019. Pharmacokinetic Drug Interactions Between Amlodipine, Valsartan, and Rosuvastatin in Healthy Volunteers. Advances in Therapy, 36 (7), 1642–1656.
Sharma, S., Chhetri, H.P., and Alam, K., 2014. A study of potential drug-drug interactions among hospitalized cardiac patients in a teaching hospital in Western Nepal. Indian Journal of Pharmacology, 46 (2), 152–156.
Son, M., Guk, J., Kim, Y., Woo Chae, D., Heo, Y.A., Soh, D., and Park, K., 2016. Pharmacokinetic Interaction Between Rosuvastatin, Telmisartan, and Amlodipine in Healthy Male Korean Subjects: A Randomized, Open-label, Multiple-dose, 2-period Crossover Study. Clinical Therapeutics, 38 (8), 1845–1857.
Teng, R., Kujacic, M., and Hsia, J., 2014. Pharmacokinetic interaction study of ticagrelor and cyclosporine in healthy volunteers. Clinical Drug Investigation, 34 (8), 529–536.
Tsai, M., Case, M., Ardayfio, P., Hochstetler, H., and Wilbraham, D., 2020. Effects of Lasmiditan on Cardiovascular Parameters and Pharmacokinetics in Healthy Subjects Receiving Oral Doses of Propranolol. Clinical Pharmacology in Drug Development, 9 (5), 629–638.
Wen, J., Zeng, M., Liu, Z., Zhou, H., Xu, H., Huang, M., and Zhang, W., 2019. The influence of telmisartan on metformin pharmacokinetics and pharmacodynamics. Journal of Pharmacological Sciences, 139 (1), 37–41.
Yang, B.B., Gillespie, B., Smith, B., Smith, W., Lissmats, A., Rudebeck, M., Kullenberg, T., and Olsson, B., 2015. Pharmacokinetic and pharmacodynamic interactions between palifermin and heparin. Journal of Clinical Pharmacology, 55 (10), 1109–1118.
